Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CHIC2
REST API REST API
Homo sapiens
CHIC2 is differentially expressed in 243 experiments: 132 organism parts: testis, lung, ... (130 more);, 171 disease states: normal, glioblastoma, ... (169 more);, 64 cell types 315 cell lines 30 compound treatments and 65 other conditions.
Synonyms BTL
Orthologs chic2 (Danio rerio)   ENSCING00000004885 (Ciona intestinalis)   Q08DD3_BOVIN (Bos taurus)   Chic2 (Rattus norvegicus)   CHIC2 (Gallus gallus)   Chic2 (Mus musculus)   CG5938 (Drosophila melanogaster)   chic2 (Xenopus laevis)   CHIC2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, Golgi-associated vesicle, Golgi apparatus, biological_process, molecular_function, cellular_component
InterPro Term Golgin_A_7/ERF4
UniProt Accession Q9UKJ5, D6RDW7
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000109220
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-19639, E-GEOD-20081
WI38
2
E-MTAB-37, E-MTAB-62
A549
2
E-GEOD-3202, E-GEOD-6013
MDA-MB-231
2
E-MTAB-62, E-TABM-420
PC3
2
E-GEOD-5258, E-MEXP-2034
U251
2
E-GEOD-20089, E-MTAB-62
309 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (31 experiments)

Factor Value U/D Experiments
neutrophil
2
E-GEOD-12662, E-GEOD-3982
articular cartilage
1
E-MEXP-2488
central memory 1 CD4 T cell
1
E-MEXP-750
plasma cell
1
E-MEXP-2360
CXCR4 negative
1
E-GEOD-15893
adipocyte
1
E-AFMX-5
58 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-22529, E-GEOD-15960, E-GEOD-1869, ... (46 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-MTAB-62, E-GEOD-4290, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
leiomyosarcoma
2
E-MEXP-1922, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-62, E-MEXP-231
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
prostate carcinoma
1
2
E-MEXP-2034, E-TABM-26, E-MTAB-62
165 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-GEOD-6462, ... (19 experiments)

Factor Value U/D Experiments
none
1
3
E-TABM-782, E-GEOD-5824, E-MEXP-1958, E-GEOD-5418
vanadium pentoxide
1
E-GEOD-5339
heregulin
1
E-GEOD-6462
chloroguine
1
E-GEOD-5418
glucose
1
E-MEXP-941
unknown
1
E-GEOD-7307
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-GEOD-21138, E-GEOD-19665

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-GEOD-2292, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-7011, E-MEXP-2657, E-TABM-127, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-GEOD-19136, ... (25 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-5820, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Processing time: 0.249 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM